Skip to content
    IDXX
    Earnings call· Jun 2025(Q2 FY25)

    IDEXX LABORATORIES INC /DE Q2 FY25 earnings call IDXX

    Aug 4, 2025 Source

    Executive summary

    IDEXX Q2 FY25 — Strong Innovation-Driven Growth Despite Clinical Visit Headwinds

    IDEXX delivered a strong quarter, driven by robust innovation and commercial execution, particularly with the rapid uptake of new platforms like inVue Dx and Cancer Dx. Despite persistent macroeconomic pressures and a decline in U.S. clinical visits, the company demonstrated resilience through strategic investments in commercial capabilities and a focus on expanding its diagnostic portfolio. Management remains confident in the long-term durability of the veterinary market and its ability to capture growth through differentiated solutions.

    Highlights

    5

    • Revenue increased 11% as reported and 9% organically in Q2 FY25.

    • CAG Diagnostic Recurring Revenues grew nearly 7.5% organically, with double-digit international expansion.

    • Record premium instrument placements reached 6,070 units, an increase of 23% year-over-year, including 2,388 IDEXX inVue DX instruments.

    • Operating profit grew 14% on a comparable basis, with operating margin expanding 130 basis points comparable.

    • Earnings per share (EPS) was $3.63, representing 17% comparable growth.

    Concerns

    2

    • U.S. same-store clinical visit growth declined 2.5% in the quarter.

    • Global Rapid assay revenues declined 3% organically, impacted by a 5% headwind from customers shifting Pancreatic Lipase Testing to the Catalyst instrument platform.

    Guidance & targets

    17
    CategoryTargetConfidence
    Full-year 2025 Revenue
    $4,205 million to $4,280 million
    high materiality
    High
    Full-year 2025 Reported Revenue Growth
    7.7% to 9.7%
    high materiality
    High
    Full-year 2025 Organic Revenue Growth
    7% to 9%
    high materiality
    High
    Full-year 2025 CAG Diagnostic Recurring Revenue Growth
    5.8% to 8%
    high materiality
    High
    Full-year 2025 inVue Dx Placements
    5,500 placements
    medium materiality
    High
    Full-year 2025 inVue Dx Instrument Revenue
    over $60 million
    medium materiality
    High
    Full-year 2025 Reported Operating Margin
    31.3% to 31.6%
    high materiality
    High
    Full-year 2025 EPS
    $12.40 to $12.76 per share
    high materiality
    High
    Full-year 2025 Comparable EPS Growth
    9% to 13%
    high materiality
    High
    Full-year 2025 Free Cash Flow Conversion
    80% to 85%
    medium materiality
    High
    Full-year 2025 Capital Spending
    approximately $160 million
    medium materiality
    High
    Q3 2025 Reported Revenue Growth
    in line with the implied second half growth range
    medium materiality
    Medium
    Q3 2025 Organic Revenue Growth
    includes U.S. clinical visit growth in line with recent trends
    medium materiality
    Medium
    Q3 2025 Comparable Operating Margin
    modest expansion
    medium materiality
    Medium
    inVue Dx FNA for lumps and bumps launch
    later this year
    medium materiality
    High
    IDEXX Cancer Dx international rollout
    2026
    medium materiality
    High
    Expanded commercial organizations
    in place by the start of 2026
    medium materiality
    High

    Segment performance

    3
    SegmentRevenueYoYQoQMargin
    Companion Animal Group (CAG)
    Strong CAG results driven by diagnostic recurring revenues and significant instrument placements, especially inVue Dx. International regions showed double-digit expansion, while U.S. growth was supported by net price realization despite clinical visit declines. VetLab consumables and software also contributed strongly.
    CAG Diagnostic Recurring Revenues organic growth: 7.5%CAG Diagnostic Instrument Revenues organic growth: 62%U.S. organic CAG Diagnostic Recurring Revenues growth: 6%International organic CAG Diagnostic Recurring Revenues growth: 11%Global average net price improvement: 4%U.S. net price realization: 3.5%U.S. clinical visits decline: 2.5%IDEXX U.S. CAG Diagnostic recurring revenue growth premium to U.S. clinical visits: 800 bpsDiagnostic frequency growth: 50 bps YoYIDEXX VetLab consumable revenues organic growth: 14%Global Reference Lab revenues organic growth: 5%Global Rapid assay revenues organic decline: 3%Veterinary software and Diagnostic imaging organic revenues growth: 9%Total premium placements: 6,070 unitsTotal premium placements YoY increase: 23%IDEXX inVue Dx placements: 2,388 unitsGlobal new and competitive Catalyst placements: 1,091 unitsNorth America new and competitive Catalyst placements: 346 unitsPremium instrument installed base YoY growth: 10%
    		—10% organic——
    Water
    Growth driven by double-digit revenue expansion in international regions and solid mid-single-digit growth in the U.S.
    		—8% organic——
    Livestock, Poultry and Dairy (LPD)
    Growth led by commercial execution in North America and Asia Pacific.
    		—3% organic——

    Operational metrics

    27
    Reported Revenue Growth
    11%
    Q2 FY25

    Overall company reported revenue growth.

    Organic Revenue Growth
    9%
    Q2 FY25

    Overall company organic revenue growth.

    Comparable Operating Profit Growth
    14%
    Q2 FY25

    Net of approximately 27% benefit from lapping a discrete litigation expense in Q2 2024.

    Comparable Operating Margin Expansion
    130
    Q2 FY25

    Net of approximately 600 basis points benefit from lapping a now concluded discrete litigation expense in Q2 2024.

    Comparable Gross Margin
    62.6%up 110 bps comparable
    Q2 FY25

    Reported gross margin gains were moderated by foreign exchange changes.

    Operating Expense Growth (adjusted)
    9%modestly below revenue growth
    Q2 FY25

    Adjusted for a 19% favorable growth rate impact from comparison to prior year levels, which included a $61.5 million litigation expense.

    EPS (share-based compensation benefit)
    $0.10
    Q2 FY25

    Benefit related to share-based compensation activity.

    EPS (discrete tax reserve release benefit)
    $0.07
    Q2 FY25

    Benefit from a discrete tax reserve release.

    Operating Profit (FX impact)
    $3 million
    Q2 FY25

    Added to operating profit, net of hedge effects.

    EPS (FX impact)
    $0.03
    Q2 FY25

    Added to EPS, net of hedge effects.

    Net Income to Free Cash Flow Conversion Rate
    80%
    TTM

    On a trailing 12-month basis.

    Long-term Notes Repaid
    $103 million
    Q2 FY25

    Amount of long-term notes repaid during the quarter.

    Share Repurchases
    $329 million
    Q2 FY25

    Capital allocated towards share repurchases during the second quarter.

    Share Repurchases (H1)
    $744 million
    H1 FY25

    Capital allocated towards share repurchases for the first half of the year.

    Diluted Shares Outstanding Reduction
    2.7%year-over-year
    H1 FY25

    Aligned with previously stated expectations.

    Revenue Outlook Operational Improvement
    $20 million
    FY25

    Operational improvement component of the increased full year revenue outlook.

    Revenue Outlook FX Benefit
    $70 million
    FY25

    Benefit from updated foreign exchange impacts in the full year revenue outlook.

    FX Sensitivity (1% USD strengthening)
    $8 million
    FY25

    Reduction in revenue for the year.

    Full-year Tax Benefit from Share-Based Compensation
    $15 millionincrease of $0.09 per share
    FY25

    Updated outlook for the full year, compared to prior estimate.

    Full-year Unfavorable Tax Impacts
    $0.02
    FY25

    Compared to prior projections, including benefits from discrete tax reserve release and updated outlook for base rate.

    Commercial Expansions
    —
    H2 FY25

    Investments to expand commercial organizations to support growing portfolio of diagnostic solutions.

    Imaging Systems Installed Base
    over 10,000
    Q2 FY25

    Surpassed this milestone in North America.

    Web PACS Subscriptions
    comparable number
    Q2 FY25

    Comparable to the imaging systems installed base, highlighting strong alignment between hardware adoption and recurring software engagement.

    Cloud-based PIMS Installed Base Growth
    solid double-digit
    Q2 FY25

    Platforms like ezyVet and Neo saw strong demand, especially for multi-location practices and corporate accounts.

    Vello Active Users Growth
    double-digit sequentialcompared to Q1
    Q2 FY25

    Continued momentum in the pet owner engagement application.

    Practices using IDEXX Cancer Dx
    over 2,500
    Q2 FY25

    Indicates broad adoption and value seen by clinicians.

    Catalyst Pancreatic Lipase Utilization
    over 40%
    Q2 FY25

    Strong uptake reflecting clinical utility and value veterinarians place on speed and accuracy.

    Industry KPIs

    12
    MetricValueDetails
    Tariff impactbest estimates included
    System utilizationhighly encouraging
    Pricing realized price4%%
    New product launch rampstrong demand
    Procedure volume growth-2.5%%
    FCF conversion leverage guidance80%%
    Installed base system placements6,070units
    Segment franchise organic growth10%%
    Consumables recurring revenue mix14%%
    Sales force commercial capacity buildexpanding
    Indicated addressable patient populationCanine lymphoma
    Pivotal trial clinical evidence milestonesSpecificity >99%, Sensitivity 79%%

    Product announcements

    2
    ProductTypeDetails
    inVue Dx FNA for lumps and bumpsroadmap
    IDEXX Cancer Dx international rolloutroadmap

    Risks & headwinds

    5
    Macro and sector headwinds impacting CAG Diagnostic Recurring Revenue growthQ2 FY25, ongoing

    Constrained CAG Diagnostic Recurring Revenue growth in Q2 FY25.

    Mitigation: IDEXX execution, innovation agenda, and commercial capabilities.

    U.S. same-store clinical visit growth declineQ2 FY25, anticipated to continue for remainder of FY25

    2.5% decline in Q2 FY25.

    Mitigation: Innovation, commercial execution, focus on diagnostic frequency and utilization, expanding role of diagnostics.

    Rapid assay revenues decline due to shift to Catalyst platformQ2 FY25

    3% organic decline in Q2 FY25, with a 5% headwind from Pancreatic Lipase Testing shift.

    Mitigation: Focus on Catalyst instrument platform adoption and expansion of its menu.

    Lingering inflationary impacts pressuring clinical visitsOngoing

    Not explicitly quantified, but cited as an ongoing pressure.

    Mitigation: Focus on executing with discipline, supporting customers through innovative solutions, and investing in capabilities.

    Dynamic trade environment / tariff landscapeOngoing

    Best estimates included in outlook.

    Mitigation: Continuous supply to customers, minimizing impacts through operational planning.

    What to watch in Q3 FY25

    5

    U.S. Clinical Visit Trends

    Next quarter
    Current-2.5% decline in Q2 FY25
    TargetStabilization or improvement in line with guidance

    Why it matters

    U.S. clinical visit trends directly impact CAG Diagnostic recurring revenue and are a key indicator of market health.

    U.S. clinical visits declined 2.5% in the quarter, reflecting an IDEXX U.S. CAG Diagnostic recurring revenue growth premium to U.S. clinical visits of approximately 800 basis points up modestly from the first quarter.

    Q&A highlights

    8

    Can you elaborate on inVue Dx uptake, the types of practices showing most traction, and if the implied H2 placement slowdown is notable?

    Management highlighted excellent customer feedback on inVue Dx's workflow and performance. The 5,500 full-year placement forecast is considered reasonable, with consumables usage tracking well. Placements are a mix of new suites and additions to existing IDEXX customers. No specific gating or slowdown is expected for H2, with FNA launch later this year expected to further drive interest.

    “the feedback we're getting from customers on inVue is excellent. It's really along two lines. One is it helps them with workflow... and also the performance, getting consistent highly accurate results is important.”

    asked by Christopher Schott · answered by Jay Mazelsky

    2 min read5 chapters

    Detailed Narrative

    01

    Innovation Driving Strong Performance

    IDEXX delivered a very strong quarter, with solid execution across key strategic drivers. The rapid uptake of new innovations, such as the inVue Dx platform and IDEXX Cancer Dx panel, along with broader adoption of software tools, significantly contributed to performance. The company's focus on supporting customers with solutions that enhance efficiency, deliver clinical insight, and support better outcomes has been critical, even as macroeconomic pressures🌐 persist.

    02

    Resilience Amidst Macroeconomic Headwinds

    Despite a 2.5% decline in U.S. clinical visits and lingering inflationary impacts, the veterinary market demonstrated durability. Pet owners continue to prioritize high-standard care for an aging pet population, supporting sustained diagnostics utilization. IDEXX's innovation and commercial execution led to a significant 800 basis point premium in U.S. CAG Diagnostic recurring revenue growth compared to clinical visits, highlighting the expanding role of diagnostics in veterinary services.

    03

    Record Instrument Placements and Installed Base Growth

    The company achieved record premium instrument placements globally, with 6,070 units placed, a 23% increase year-over-year. This was significantly aided by the broad availability and strong demand for inVue Dx, which saw 2,388 placements in Q2. The quality of placements remains high, with 1,091 global new and competitive Catalyst placements, contributing to a 10% year-over-year growth in the premium instrument installed base.

    04

    Strategic Commercial Investments and International Momentum

    IDEXX is making strategic commercial investments to expand in three additional international countries and modestly enhance its U.S. commercial team, with these organizations expected to be in place by early 2026. These investments are aimed at increasing commercial density and supporting a broader portfolio of diagnostic products. International regions continued to show strong performance, with 11% organic growth in CAG Diagnostics recurring revenue, marking the tenth consecutive quarter of double-digit installed base growth.

    05

    Expanding Diagnostic Menu and Software Ecosystem

    New product launches like Catalyst Cortisol in North America and the continued strong adoption of Catalyst Pancreatic Lipase underscore IDEXX's commitment to expanding its platform's menu. The software ecosystem, including cloud-based PIMS platforms (ezyVet, Neo) and the Vello pet owner engagement application, continues to drive efficiency, patient care, and incremental recurring revenues. The Diagnostic Imaging business also surpassed 10,000 installed systems in North America, with comparable Web PACS subscriptions.

    AI-generated summary of the company’s earnings call. Not investment advice.